GSK invites private equity bids for older drugs -sources
LONDON May 29 (Reuters) - GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, according to two people with direct knowledge of the matter.
The move is part of a reshaping of the drugmaker's business, which also involves a major asset swap deal with Novartis .
Chief Executive Andrew Witty said last month that Britain's biggest pharmaceuticals company could dispose of individual medicines or a broader portfolio of older established products. A GSK spokesman had no further comment on potential disposals on Thursday. (Reporting by Ben Hirschler; editing by Jon Boyle)
- Gaza fighting abates as diplomatic tension flares |
- Hague court orders Russia to pay over $50 billion in Yukos case
- Man found dead trapped between elevator and shaft wall in NYC
- Europe nervy as Russian assets hit by new sanctions talk
- Ukraine troops advance as experts renew attempt to reach crash site